MARC Record from marc_columbia

LEADER: 06032cam a22004454a 4500
001 5794837
005 20221121204247.0
008 051216t20062006nyua b 001 0 eng
010 $a 2005036791
016 7 $a101263798$2DNLM
020 $a0849327792 (alk. paper)
024 3 $a9780849327797
029 1 $aNLM$b101263798
035 $a(OCoLC)ocm62736887
035 $a(NNC)5794837
035 $a5794837
040 $aDNLM/DLC$cDLC$dNLM$dBAKER$dC#P$dOrLoB-B
042 $apcc
050 00 $aRM301.25$b.S55 2006
060 10 $aQV 744$bP9645 2006
082 00 $a615/.19$222
245 04 $aThe process of new drug discovery and development /$cedited by Charles G. Smith, James T. O'Donnell.
250 $a2nd ed.
260 $aNew York :$bInforma Healthcare,$c[2006], ©2006.
300 $a668 pages :$billustrations ;$c27 cm
336 $atext$btxt$2rdacontent
337 $aunmediated$bn$2rdamedia
505 00 $g1.$tIntroduction /$rCharles G. Smith -- $g2.$tOverview of the current process of new drug discovery and development /$rCharles G. Smith and James T. O'Donnell -- $g3.$tIntegrated drug product development - from lead candidate selection to life-cycle management /$rMadhu Pudipeddi, Abu T. M. Serajuddin and Daniel Mufson -- $g4.$tThe impact of combinatorial chemistry on drug discovery /$rMichael H. Rabinowitz and Nigel Shankley -- $g5.$tHigh-throughput screening : enabling and influencing the process of drug discovery /$rCarol Ann Homon and Richard M. Nelson -- $g6.$tPharmacological and pharmaceutical profiling : new trends /$rJoanne Bowes, Michael G. Rolf, Jean-Pierre Valentin, Valerie Hamon, Mark Crawford and Thierry Jean -- $g7.$tCell-based analysis of drug response using moving optical gradient fields /$rJeff M. Hall, Ilona Kariv, Patricia A. McNeeley, Phillip J. Marchand and Tina S. Nova -- $g8.$tPatient-derived primary cells in high-throughput differential antitumor screens : let the patients be the guide /$rIrwin A. Braude -- $g9.$tThe evolving role of the Caco-2 cell model to estimate intestinal absorption potential and elucidate transport mechanisms /$rJibin Li and Ismael J. Hidalgo -- $g10.$tThe promise of metabonomics in drug discovery /$rHarold J. Kwalwasser and Pauline Gee -- $g11.$tPharmacogenetics and pharmacogenomics in drug development and regulatory decision-making : report of the first FDA-PWG-PhRMA-DruSafe workshop /$rLawrence J. Lesko, Ronald A. Salerno, Brian B. Spear, Donald C. Anderson, Timothy Anderson, Celia Brazell, Jerry Collins, Andrew Dorner, David Essayan, Baltazar Gomez-Mancilla, Joseph Hackett, Shiew-Mei Huang, Susan Ide, Joanne Killinger, John Leighton, Elizabeth Mansfield, Robert Meyer, Stephen G. Ryan, Virginia Schmith, Peter Shaw, Frank Sistare, Mark Watson and Alexandra Worobec -- $g12.$tDrugs from molecular targets for CNS and neurodegenerative diseases /$rWilliam T. Comer and Gonul Velicelebi -- $g13.$tSafety pharmacology : past, present, and future /$rJean-Pierre Valentin and Tim G. Hammond -- $g14.$tNonclinical drug safety assessment /$rFrederick E. Reno -- $g15.$tPreclinical genotoxicity testing - past, present, and future /$rRichard H. C. San -- $g16.$tThe need for animals in biomedical research /$rCharles G. Smith -- $g17.$tDefining the actual research approach to the new drug substance /$rCharles G. Smith -- $g18.$tPharmacokinetics - pharmacodynamics in new drug development /$rSarfaraz K. Niazi -- $g19.$tPharmaceutics and compounding issues in new drug development and marketing /$rLoyd V. Allen -- $g20.$tLate stage and process development activities /$rCharles G. Smith -- $g21.$tContract research organizations : role and function in new drug development /$rF. Richard Nichol -- $g22.$tThe front lines of clinical research : the industry /$rLori Nesbitt -- $g23.$tHorizons for cancer chemotherapy (and nonchemotherapy) /$rDaniel D. Von Hoff -- $g24.$tHuman immunodeficiency virus/acquired immune deficiency syndrome : clinical testing challenges /$rVincent Idemyor -- $g25.$tCommon technical document : the changing face of the new drug application /$rJustina A. Molzon -- $g26.$tElectronic publishing /$rHeather L. Wallace -- $g27.$tThe important role of pharmacists in a complex risk-management system : managing the risks from medical product use by focusing on patient education, monitoring, and adverse event reporting /$rJustina A. Molzon -- $g28.$tLiability, litigation, and lessons in new drug development /$rJames T. O'Donnell -- $g29.$tProblems in the nondrug marketplace /$rStephen Barrett -- $g30.$tPatents and new product development in the pharmaceutical and biotechnology industries /$rHenry Grabowski -- $g31.$tThe pharmaceutical revolution : drug discovery and development /$rJohn C. Somberg -- $g32.$tThe discovery of Rituxan /$rMitchell E. Reff -- $g33.$tFunding the birth of a drug : lessons from the sell side /$rHoward E. Greene -- $g34.$tInnovations for the drug development pathway : what is needed now /$rJanet Woodcock -- $g35.$tManaging R&D uncertainty and maximizing the commercial potential of pharmaceutical compounds using the dynamic modeling framework /$rMark Paich, Corey Peck, Jason Valant and Kirk Solo.
500 $aRev. ed. of: The process of new drug discovery and development / Charles G. Smith. c1992.
504 $aIncludes bibliographical references and index.
650 0 $aDrugs$xResearch$xHistory.
650 0 $aDrugs$xDesign$xHistory.
650 12 $aDrug Design.$0https://id.nlm.nih.gov/mesh/D015195
650 22 $aDrug Evaluation, Preclinical.$0https://id.nlm.nih.gov/mesh/D004353
650 22 $aDrug Evaluation.$0https://id.nlm.nih.gov/mesh/D004341
700 1 $aSmith, Charles G.$q(Charles Giles)$0http://id.loc.gov/authorities/names/n92801380
700 1 $aO'Donnell, James,$cPharm. D.$0http://id.loc.gov/authorities/names/n95026876
856 41 $3Table of contents$uhttp://www.loc.gov/catdir/toc/ecip065/2005036791.html
856 42 $3Publisher description$uhttp://www.loc.gov/catdir/enhancements/fy0647/2005036791-d.html
852 00 $boff,hsl$hRM301.25$i.S55 2006